Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.

被引：4
|
作者：
Loibl, Sibylle
Majewski, Ian
Guarneri, Valentina
Nekljudova, Valentina
Holmes, Eileen McCormick
Bria, Emilio
Denkert, Carsten
Eidtmann, Holger
Sotiriou, Christos
Loi, Sherene
Andre, Fabrice
Untch, Michael
Conte, Pier Franco
Piccart-Gebhart, Martine J.
Von Minckwitz, Gunter
Baselga, Jose
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Univ Padua, IRCCS, Ist Oncol Veneto, Padua, Italy
[4] Frontier Sci Scotland, Kingussie, Inverness, Scotland
[5] Univ Verona, I-37100 Verona, Italy
[6] Charite, Inst Pathol, D-13353 Berlin, Germany
[7] Univ Kiel, Kiel, Germany
[8] Inst Jules Bordet, B-1000 Brussels, Belgium
[9] Peter MacCallum Canc Ctr, East Melbourne, Australia
[10] Inst Gustave Roussy, Villejuif, France
[11] Helios Klinikum Berlin Buch, Berlin, Germany
[12] IOV IRCCS, Inst Oncol Veneto, Padua, MO, Italy
[13] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1519 - 1525
  • [2] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2151 - 2151
  • [3] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1180 - 1180
  • [4] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab (vol 27, pg 1519, 2016)
    Loibl, S.
    Majewski, I
    Guarneri, V
    Nekljudova, V
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1075 - 1075
  • [5] Clinico-pathological Features of PIK3CA Mutation in HER2-Positive Breast Cancer of Indian Population
    Saikia K.K.
    Panigrahi M.K.
    Mehta A.
    Kumar D.
    Indian Journal of Surgical Oncology, 2018, 9 (3) : 381 - 386
  • [6] PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
    Loibl, Sibylle
    Denkert, Carsten
    Loi, Sherene
    Andre, Fabrice
    Mueller, Berit
    Schneeweiss, Andreas
    Blohmer, Jens U.
    Jackisch, Christian
    Guo Sanxing
    Gade, Stephan
    Fasching, Peter A.
    Schem, Christian
    Sotiriou, Christos
    Untch, Michael
    Von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [8] Targeting PIK3CA in HER2-positive breast cancer: what are the opportunities and the challenges?
    Zouein, Joseph
    Noujaim, Charbel
    Kourie, Hampig Raphael
    BIOMARKERS IN MEDICINE, 2021, 15 (09) : 609 - 613
  • [9] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [10] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
12345